[18F]DCFPyL Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This [18F]DCFPyL Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether [18F]DCFPyL can convert its Small molecule drug, Diagnostic radiopharmaceuticals profile and PSMA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | [18F]DCFPyL (query alias: [18F]DCFPyL) |
|---|---|
| Modality / target | Small molecule drug, Diagnostic radiopharmaceuticals; PSMA; PSMA inhibitors, PET imaging |
| Highest global status | Approved |
| Originator | Progenics Pharmaceuticals, Inc. |
| Active developers | Lantheus Medical Imaging, Inc., The Johns Hopkins University, Progenics Pharmaceuticals, Inc. |
The MCP disease footprint includes PSMA-Positive Prostatic Cancer, Prostatic Cancer, Breast Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07084909 | Phase 2/3 | Withdrawn | Not disclosed | Phase 2 Primary Objective - Establishing the optimum dose and timing window of piflufolastat F18 for detection of metastatic disease |
| NCT06904313 | Phase 2 | Recruiting | 200 | Signal-to-Noise Ratio (SNR) |
| NCT06881823 | Phase 1/2 | Withdrawn | Not disclosed | Number of participants with dose-limiting toxicities (DLTs) (Phase l) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Phase 4; n=62; evaluation: not stated. Reported fields: To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.(Median): Median Difference (Final Values) = 15.1, P-Value = <0.001; To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.(Median): Median Difference (Final Values) = 15.1, P-Value = <0.001; To Compare Urinary Bladder Radioactivity Observed on Piflufolastat (18F) PET and Flotufolastat (18F) PET.(Median): Median Difference (Final Values) = 15.1, P-Value = <0.001
FDA-Approved Drugs-PYLARIFY TRUVU-CLINICAL STUDIES (Ⅰ)
Phase 2/3; n=252; evaluation: Positive. Reported fields: Sensitivity(Reader 1) = 39 % (95%CI, 27 - 51)
FDA-Approved Drugs-PYLARIFY TRUVU-CLINICAL STUDIES (Ⅱ)
Phase 3; n=208; evaluation: Positive. Reported fields: CLR(Reader 1) = 86 % (95%CI, 79 - 92)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
[18F]DCFPyL addresses PSMA-Positive Prostatic Cancer, Prostatic Cancer, Breast Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug, Diagnostic radiopharmaceuticals—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-23 | Synektik Pharma entered into an agreement to manufacture and distribute Curium Pharma 's Pylclari for prostate cancer in Poland | Approved | Financial terms not disclosed |
| 2025-09-24 | Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan | Approved | Financial terms not disclosed |
| 2022-03-29 | Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
